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Abstract
A new series of hybrid compounds were designed, consisting of anti-AChE and BuChE activity components with an anti-
inflammatory component. A series of 9-amino-1,2,3,4-tetrahydroacridine and indomethacin derivatives were synthesized. 
All compounds were created using alkyldiamine with different chain lengths as a linker. Various biological activities were 
evaluated, including inhibitory activity against AChE and BuChE. The tested compounds showed high inhibitory activities 
against cholinesterases. The  IC50 values for all compounds ranging from 10 nM to 7 µM. The potency of inhibition was much 
higher than well-known AChE and BuChE inhibitors (tacrine and donepezil). Compound 3h had the strongest inhibitory 
activity; kinetic studies showed it to have a mixed-type of acetylcholinesterase inhibition properties. The cytotoxicity of 
the newly-synthesized compounds against HepG2 (hepatocarcinoma cells) and EA.hy96 (human vein endothelial cells) cell 
lines was determined using the MTT and MTS tests. All investigated compounds presented similar cytotoxic activity against 
HepG2 and EA.hy926 cell line, ranged in micromolar values. Compounds with longer linkers showed higher antioxidant 
activity. The most active compound was 3h. Docking studies confirmed interactions with important regions of AChE and 
BuChE. Its multifunctional properties, i.e. high activity against AChE and BuChE, antioxidant activity and low cytotoxicity, 
highlight 3h as a promising agent for the treatment of AD.
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CNS  Central nervous system
MAPT  Microtubule-associated protein tau
NFTs  Neurofibrillary tangles
NSAIDs  Nonsteroidal anti-inflammatory drugs
PGH2  Prostaglandin H2
CDMT  2-Chloro-4,6-dimethoxy-1,3,5-triazine
THF  Tetrahydrofuran
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The most common human neurodegenerative disease is Alz-
heimer’s disease (AD)—which was described for the first 
time by Alois Alzheimer over 100 years ago. AD causes
a significant decrease in cognitive abilities in people 
over 60 years old (Obulesu and Jhansilakshmi 2014). The 
incidence of AD increases with age: rising from 5% among 
people aged 65–50% over the age 85 (Townsend and Praticò 
2005). The disease has a progressive and multifunctional 
character. Its development involves a lot of factors but a com-
plete etiology has not been discovered (Tayeb et al. 2012) 
and no method exists which can be used to treat AD (Côté 
et al. 2012). Existing drugs only slow the progression of the 
disease and slightly improve patient comfort and everyday 
life. Previous studies of AD pathophysiology have examined 
the formation of β-amyloid deposits, prolonged oxidative 
stress, cholinergic system dysfunctions (Tayeb et al. 2012; 
Zimmer et al. 2014; Blass 2002), inflammations, aging, heart 
disease, hypertension, hypercholesterolemia, diabetes, gene 
mutations associated with the incorrect tau protein (Cataldo 
et al. 2010), as well as the imbalance of bio-metals (Tayeb 
et al. 2012; Huang et al. 2014).
Autopsy of AD patient shows cholinergic system dys-
function in the brain, as well as disorders of ACh, choline, 
and choline acetyltransferase levels. AD is characterized by 
ongoing neuron damage, resulting in decreasing levels of 
neurotransmitters, mainly acetylcholine (ACh). This damage 
leads to a deterioration of cognitive abilities and memory 
loss (Zemek et al. 2014; Allgaier and Allgaier 2014; Volpato 
and Holzgrabe 2018).
Most of the currently used treatment methods are based 
on raising the ACh levels in synapses. Acetylcholinesterase 
(AChE) and butyrylcholinesterase (BuChE) facilitate the 
hydrolysis of acetylcholine in the synaptic cleft to choline 
and acetate. AChE is present in the Central Nervous Sys-
tem (CNS), neuromuscular synapses and red blood cells; 
BuChE in the CNS, liver, plasma and lungs. AChE hydro-
lyzes acetylcholine faster than BuChE (Czarnecka et al. 
2017). Among the receptors of the cholinergic system, the 
most important are muscarinic (mAChRs) and nicotinic 
(nAChRs) acid. The former binds with G-protein, while the 
latter regulates the opening of ion channels. The M1 recep-
tor subtype is present in large numbers in the hippocampus 
and cerebral cortex and plays an important role in cognitive 
abilities and learning.
M1 muscarinic receptors can be a potential target for new 
medicines against AD. Some of the tested compounds act-
ing on M1 receptors were found to reduce oxidative stress 
and amyloid β deposits. The APP metabolic pathway is con-
verted to nonamyloidogenic pathway when these compounds 
bind to the M1 receptors. Nicotinic receptors are transmem-
brane proteins that act as ionic channels. They consist of two 
subunits (α and β) and a hydrophilic centre. Nicotinic recep-
tors mediate the flow of  Na+,  K+ and  Ca2+. Different kinds 
of nicotinic receptors with different combinations of α and 
β subunits have been distinguished. Amyloid β stimulates 
nicotinic receptors: nAChRs α7 at physiological concentra-
tions, and α7 and α4β2 at pathological concentrations (Chen 
et al. 2013a, b; Volpato and Holzgrabe 2018).
Donepezil, rivastigmine and galantamine have been gen-
erally approved and are currently used in AD therapy. These 
compounds have the ability to cross the blood–brain barrier 
and inhibit AChE and BuChE (Chen et al. 2013a, b). Gal-
antamine also has inhibitory properties against β-amyloid 
aggregation (Ng et al. 2015). Memantine protects neurons 
against neurotoxic long-term overexposure of the glutamate 
receptor (Kurz and Perneczky 2011). Tacrine (9-amine-
1,2,3,4-tetrahydroacridine) has been withdrawn from use 
because of high its hepatotoxicity associated with increased 
serum alanine aminotransferase activity (Tayeb et al. 2012; 
Park et al. 2015).
Multitarget compounds such as hybrids composed of 
ligands with different pharmacological properties may rep-
resent an effective treatment for the complex pathophysiol-
ogy of AD. New hybrids can act simultaneously on proteins 
involved in different metabolic pathways, such as AChE and 
cholinergic receptors. Another strategy is to create a hybrid 
acting on one protein but in different places: orthosteric 
inside the structure and allosteric on the surface. Ligands 
can modify the activity of the enzyme by changing its con-
formation. Hybrids may act on the G-protein associated with 
mAChRs receptors (Volpato and Holzgrabe 2018). Due to its 
strong inhibitory activity, tacrine derivatives connected with 
other moieties possess lower toxic properties and higher 
potency against AChE and BuChE (Chen et al. 2013a, b).
Tacrine hybrids have been investigated for over 20 years 
as a part of multi-target strategy of AD treatment. The 
desired hybrid is a molecule that can act simultaneously 
on different proteins, on different fragments of the same 
protein or on different pathways in the pathogenesis of the 
disease (Volpato and Holzgrabe 2018). Such compounds 
are 1,2,3,4-tetrahydroacridine and various 4-fluorobenzoic 
acid derivatives which demonstrate high potency against 
AChE, which selectivity was determined enzymatically 
(Szymanski et al. 2011). Similarly, tacrine hybrids with 2- 
or 3-fluorobenzoic acid inhibit AChE/BuChE and demon-
strate inhibitory properties against amyloid-β aggregation 
(Czarnecka et al. 2017). Tacrine–flavonoid hybrids show 
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inhibitory potency against cholinesterases and amyloid-β 
aggregation, and have metal chelating properties (Li et al. 
2013). Tacrine–flurbiprofen derivatives, characterized by 
higher inhibitory potency against AChE and BuChE than 
tacrine alone, inhibit amyloid-β aggregation. They bind to 
the catalytic active site and peripheral anionic site of cho-
linesterase (Chen et al. 2013a, b). Tacrine hybrids with 
8-hydroxycholine have neuroprotective, cholinergic, anti-
oxidant and copper-complexing properties (Fernandez-
Bachiller et al. 2010).
The Aβ peptide is formed in the hydrolysis process from 
amyloid precursor protein (APP). β-Amyloid contains from 
39 to 42 amino acids in the peptide chain (Meraz-Ríos et al. 
2013). The most important in AD progression is Aβ, con-
structed from 40 amino acids (Aβ40) and 42 amino acids 
(Aβ42) (Chen et al. 2013a, 2013b; Carreras et al. 2013). 
Aβ42 has higher potency to aggregate, be deposited in the 
CNS and is more neurotoxic than Aβ40 (Czarnecka et al. 
2017). They are created in the proteolysis of APP by two 
enzymes: β-secretase and γ-secretase (Tayeb et al. 2012).
Some gene mutations increase Aβ production. Presenilins 
1 and 2 are catalytic components of γ-secretase—mutations 
in presenilin genes disturb the Aβ40/Aβ42 ratio (Townsend 
and Praticò 2005). High γ-secretase activity is also induced 
by cytokines and reactive oxygen species (Ng et al. 2015). 
Additional β-amyloid binds with AChE in complexes, and 
these have much higher potency to create deposits than 
β-amyloid alone. Moreover, ions of zinc, copper and iron 
are catalysts in the process of forming Aβ fibrils (Kurz and 
Perneczky 2011).
Other factors responsible for the development of AD is 
the synthesis of pathological MAPT (microtubule associated 
with protein tau), caused by gene mutations or an imbal-
ance between kinases and phosphatases (Bajda et al. 2015; 
Medina and Avila 2014). Tau protein forms microtubules in 
the cell skeleton, particularly in the neurons. As a result of 
tau protein hyperphosphorylation, neurotoxic neurofibrillary 
tangles (NFT) are created (Obulesu and Jhansilakshmi 2014; 
McGeer 2000). The presence of Aβ42 induces phosphoryla-
tion of tau protein (Tayeb et al. 2012; Kurz and Perneczky 
2011; Berk et al., 2013). Pathological tau protein deposits 
result in the destabilization of the cytoskeleton and impaired 
conduction of impulses by axons (Bajda et al. 2015).
AD is characterized by the occurrence of inflammation 
in the brain (Townsend and Praticò 2005; Results of a fol-
low-up study to the randomized Alzheimer’s Disease Anti-
inflammatory Prevention Trial (ADAPT) 2013). Cytokines 
and prostaglandins play key roles in the complicated inflam-
matory process. Cytokines and prostaglandins are formed as 
a result of the action of cyclooxygenase (COX) (Townsend 
and Praticò 2005; McGeer 2000). Research showed that 
cytokines and prostaglandins  (PGH2 mainly) increase the 
synthesis of neurotoxic Aβ42 and its deposition in the CNS 
(Results of a follow-up study to the randomized Alzheimer’s 
Disease Anti-inflammatory Prevention Trial (ADAPT) 
2013). The discovery that inflammation in the CNS is one 
of the main factors in AD development encouraged research 
into nonsteroidal anti-inflammatory drugs (NSAIDs) as 
potential treatments (Imbimbo et al. 2010). NSAIDs reduce 
the synthesis of prostaglandins and cytokines by inhibiting 
cyclooxygenase and secretase-γ activity (Chen et al. 2013a, 
b; Cudaback et al. 2014; Prati et al. 2013). They exhibit 
good potency to decrease β-amyloid synthesis and create 
deposits. Research showed that the application of NSAIDs 
such as ibuprofen, flurbiprofen, sulindac and indomethacin 
can decrease of the synthesis of Aβ42 and change the APP 
metabolism towards the less neurotoxic Aβ40 (Prati et al. 
2013).
Prolonged oxidative stress, i.e. an imbalance between 
the formation of oxygen and nitrogen free radicals and their 
removal, damages neurons. Free radicals are molecules 
that contain unpaired electrons. Oxidative stress damages 
DNA, lipids, carbohydrates and proteins inside the cells, and 
neurons are particularly vulnerable. Homoeostasis is main-
tained by endogenous antioxidants; however, in the case of 
prolonged imbalance, the cellular metabolism undergoes 
deregulation: phosphorylation intensifies, pro-inflammatory 
factors are formed and inflammation develops. Cu and Fe 
demonstrate strong redox properties and cause the forma-
tion of free oxygen radicals. Reactive forms of oxygen and 
nitrogen, together with pro-inflammatory factors, intensify 
the synthesis and aggregation of Aβ 1-42 (Berk et al. 2013; 
Chen et al. 2011; Solleiro-Villavicencio and Rivas-Arancibia 
2018).
In 2019, new hybrids of indole-3-acetic acid (IAA) and 
tacrine, connected by aliphatic linker were synthesized. The 
compound with six C atoms in the linker showed similar 
activity against AChE and higher activity against BuChE 
compared to tacrine. The most active compound was found 
to interact with both CAS and PAS of ChE. The basic nitro-
gen atom in the structure of the tested compound is respon-
sible for binding with aromatic residues of amino acids in 
the active site of the enzyme. Additional de novo synthe-
sized compounds do not show cytotoxic side effect relative 
to HepG2 (Cheng et al. 2019).
Research into tacrine–indomethacin hybrids and their 
potency to inhibit AChE and BuChE is ongoing. New 
hybrids based on acetylcholinesterase inhibitors have been 
found to both increase the ACh level and decrease the 
amount of β-amyloid deposits (Czarnecka et al. 2017). The 
aim of the present study was to create a new tacrine deriva-
tive with indomethacin moieties. It has previously been 
found that indomethacin with an indole ring in its struc-
ture with the N atom enhances the interaction between the 
hybrids and the cholinesterase in CAS and PAS (Cheng 
et al. 2019). Their potency against AChE and BuChE and 
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selectivity was studied. Among the compounds obtained, 
those that showed the highest inhibitory potency were 
selected for cytotoxic and antioxidant evaluation. Moreover, 
molecular modeling and docking studies were performed to 
determine the structure of the synthesized compounds and 
how they interact with cholinesterases.
Experimental: materials and methods
Anhydrous  Na2SO4 (Sigma-Aldrich) was used to dry the 
organic solutions. The solvents were then evaporated under 
vacuum with a rotary evaporator. Reactions were checked 
by TLC analysis, for which the 25 DC-Alufolien Kiesel-
gel 60F254 (Merck) and UV Lamp (254 nm) were used. 
The reaction products were purified by flash chromatogra-
phy (column 50 μm SiHP, 12 g Interchim) with methylene 
chloride (methylene chloride: methanol: 30%NH3; 10:1:0.2) 
gradient elution. Melting points for 2a–2h and 3a–3h were 
measured in open capillaries on the electrothermal appa-
ratus. The IR spectra of 2a–2h, 3a–3h were recorded in 
attenuated total reflectance (ATR) mode (Thermo Scientific 
Nicolet 6700). Fourier transform infrared spectrometer with 
smart ITR diamond adapter (Madison, Wisconsin USA) was 
used. An Agilent Accurate-Mass Q-TOF LC/MS G6520B 
system with a dual electrospray source (Agilent Technolo-
gies, Santa Clara, USA) were used to obtain mass spectra. 
The detector was set in a positive mode with the use of 
Agilent ESI-L (high-resolution mode—4 GHz). 1H NMR 
spectra were recorded by Bruker Avance III 600 MHz spec-
trometer, where tetramethylsilane was used as the internal 
standard.
General procedure for the synthesis of compounds 
2a–2h
Step “a” in Scheme 1 was carried out to obtain compounds 
2a–2h. 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-
3-yl]acetic acid (Indomethacin, Sigma-Aldrich) and N-meth-
ylmorpholine (as a water absorber) (Sigma-Aldrich) were 
added to a solution of 2-chloro-4,6-dimethoxy-1,3,5-triazine 
(CDMT, condensation agent, activator) (Sigma-Aldrich) 
in  tetrahydrofuran (10 mL) (THF, as a solvent) (Sigma-
Aldrich). The solution was stirred at room temperature for 
3 h. A solution of compounds 1a–1h dissolved in tetrahy-
drofuran (3 mL) (Sigma-Aldrich) (THF, as a solvent) was 





The solution of 2-[1-(4-chlorobenzoyl)-5-methoxy-
2-methylindol-3-yl]acetic acid (0.12  g; 0.34  mmol), 
2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (0.06 g; 
0.34 mmol), N- methylmorpholine (0.04 mL; 0.36 mmol) 
and tetrahydrofuran (THF) (10  mL), the solution of 
Scheme 1  Synthesis of 3a–3h. 
Reagents: [a]—indomethacin, 
CDMT, N-methylmorpholine, 
− 5 °C, 24 h; [b]—1.0 M HCl in 
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N-(1,2,3,4-tetrahydro-9-acrdinyl)-1,2-ethanediamine 
(0.08  g; 0.33  mmol, 1a) dissolved in  tetrahydrofuran 
(THF) (3  mL) was added. Yield 12.58%, orange solid; 
mp 163-165  °C. FTIR (ATR) v  (cm−1): 749.6, 1224.1, 
1324.1, 1475.2, 1588.8, 2939.6, 3184.8; 1H NMR 1H 
NMR (600 MHz, Chloroform-d) δ 8.27 (1H, d, J = 8.4 Hz, 
Ar), 8.11 (1H, d, J = 8.8 Hz, Ar), 7.67–7.71 (2H, m, Ar), 
7.44–7.49 (3H, m, Ar), 7.25 (1H, t, J = 7.9 Hz, Ar), 7.03 
(1H, s, Ar), 6.87 (1H, d, J = 9.0 Hz, Ar), 6.60–6.63 (1H, m, 
Ar), 4.07–4.10 (2H, m,  CH2), 4.06 (3H, s,  CH2), 3.78 (3H, 
s,  CH2), 3.75 (2H, q, J = 5.8 Hz,  CH2), 3.52 (1H, s,  CH2), 
3.14 (2H, t, J = 6.0 Hz,  CH2), 2.48 (1H, t, J = 5.9 Hz,  CH2), 
1.72–1.81 (4H, m,  CH2); MS (ESI) m/z (M + 1) 581.2, 199.1, 





The solution of 2-[1-(4-chlorobenzoyl)-5-methoxy-2-meth-
ylindol-3-yl]acetic acid (0.38 g; 1.06 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (CDMT) (0.19 g; 1.08 mmol), 
N- methylmorpholine (0.12 mL; 1.09 mmol) and tetrahydro-
furan (THF) (10 mL), the solution of N-(1,2,3,4-tetrahydro-
9-acrdinyl)-1,3-propanediamine (0.27 g; 1.06 mmol, 1b) dis-
solved in tetrahydrofuran (THF) (3 mL) was added. Yield 
82.64%, beige solid; mp 143–145 °C. FTIR (ATR) v  (cm−1): 
753.6, 1227.7, 1313.8, 1477.5, 1570.4, 2937.9, 3230.2; 1H 
NMR (600 MHz, Chloroform-d) δ 8.49 (1H, d, J = 8.3 Hz, 
Ar), 8.18 (1H, d, J = 8.6 Hz, Ar), 7.66–7.72 (3H, m, Ar), 
7.49–7.52 (2H, m, Ar), 7.44 (1H, t, J = 8.1 Hz, Ar), 7.00 (1H, 
s, Ar), 6.86 (1H, d, J = 9.0 Hz, Ar), 6.70 (1H, d, J = 11.5 Hz, 
Ar), 3.85–3.89 (2H, m,  CH2), 3.82 (3H, s,  CH2), 3.78 (3H, 
s,  CH2), 3.52 (1H, s,  CH2), 3.46 (2H, q, J = 6.3 Hz,  CH2), 
3.31 (2H, t, J = 6.3 Hz,  CH2), 2.77 (2H, t, J = 6.2 Hz,  CH2), 
1.86–1.98 (6H, m,  CH2); MS (ESI) m/z (M + 1) 595.2, 199.1, 





The solution of 2-[1-(4-chlorobenzoyl)-5-methoxy-2-meth-
ylindol-3-yl]acetic acid (0.16 g; 0.45 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (CDMT) (0.08 g; 0.45 mmol), 
N- methylmorpholine (0.05 mL; 0.45 mmol) and tetrahy-
drofuran (THF) (10 mL), the solution of N-(1,2,3,4-tetrahy-
dro-9-acrdinyl)-1,4-butanediamine (0.12 g; 0.45 mmol; 
1c) dissolved in tetrahydrofuran (THF) (3 mL) was added. 
Yield 37.33%, yellow solid; mp 132–134 °C. FTIR (ATR) 
v  (cm−1): 754.1, 1224.2, 1323.5, 1474.6, 1573.8, 2938.7, 
3238.8; 1H NMR (600 MHz, Chloroform-d) δ 8.45 (1H, d, 
J = 8.6 Hz, Ar), 8.15 (1H, d, J = 8.6 Hz, Ar), 7.64–7.71 (3H, 
m, Ar), 7.49–7.52 (2H, m, Ar), 7.43 (1H, t, J = 7.5 Hz, Ar), 
6.98 (1H, s, Ar), 6.86 (1H, d, J = 9.0 Hz, Ar), 6.67 (1H, d, 
J = 11.5 Hz, Ar), 3.87–3.92 (2H, m,  CH2), 3.79 (3H, s,  CH2), 
3.71 (3H, s,  CH2), 3.52 (1H, s,  CH2), 3.34 (2H, q, J = 6.6 Hz, 
 CH2), 3.27 (2H, t, J = 6.2 Hz,  CH2), 2.61 (2H,t, J = 6.1 Hz, 
 CH2), 1.78–1.95 (6H, m,  CH2), 1.62–1.69 (2H, m,  CH2); MS 
(ESI) m/z (M + 1) 609.3, 199.1, 143.0; MS-HR (ESI) Calcd 




The solution of 2-[1-(4-chlorobenzoyl)-5-methoxy-2-meth-
ylindol-3-yl]acetic acid (0.29 g; 0.81 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (CDMT) (0.14 g; 0.79 mmol), 
N- methylmorpholine (0.09 mL; 0.82 mmol) and tetrahy-
drofuran (THF) (10 mL), the solution of N-(1,2,3,4-tetrahy-
dro-9-acrdinyl)-1,5-pentanediamine (0.23 g; 0.81 mmol; 
1d) dissolved in tetrahydrofuran (THF) (3 mL) was added. 
Yield 42.98%, yellow solid; mp 134–136 °C. FTIR (ATR) 
v  (cm−1): 754.1, 1224.2, 1323.7, 1474.5, 1569.7, 2937.4, 
3238.2; 1H NMR (600 MHz, Chloroform-d) δ 8.54 (1H, d, 
J = 7.8 Hz, Ar), 8.18 (1H, d, J = 8.6 Hz, Ar), 7.66–7.73 (3H, 
m, Ar), 7.49–7.52 (2H, m, Ar), 7.45 (1H, t, J = 8.1 Hz, Ar), 
6.93 (1H, s, Ar), 6.84 (1H, d, J = 9.0 Hz, Ar), 6.68 (1H, 
d, J = 11.5 Hz, Ar), 3.84–3.88 (2H, m,  CH2), 3.80 (3H, s, 
 CH2), 3.69 (3H, s,  CH2), 3.52 (1H, s,  CH2), 3.33 (2H, t, 
J = 6.1 Hz,  CH2), 3.29 (2H, q, J = 6.6 Hz,  CH2), 2.62 (2H, 
t, J = 6.2 Hz,  CH2), 1.81–1.98 (6H, m,  CH2), 1.55 (2H, p, 
J = 7.0 Hz,  CH2), 1.43 (2H, p, J = 7.7 Hz,  CH2); MS (ESI) 
m/z (M + 1) 623.3, 199.1, 143.0; MS-HR (ESI) Calcd for 




The solution of 2-[1-(4-chlorobenzoyl)-5-methoxy-2-meth-
ylindol-3-yl]acetic acid (0.30 g; 0.84 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (CDMT) (0.15 g; 0.85 mmol), 
N- methylmorpholine (0.09 mL; 0.82 mmol) and tetrahy-
drofuran (THF) (10 mL), the solution of N-(1,2,3,4-tetrahy-
dro-9-acrdinyl)-1,6-hexanediamine (0.25 g; 0.84 mmol; 
1e) dissolved in tetrahydrofuran (THF) (3 mL) was added. 
Yield 15.59%, brown solid; mp 145–147 °C. FTIR (ATR) 
v  (cm−1): 754.2, 1224.1, 1357.5, 1474.6, 1588.3, 2932.1, 
3231.6; 1H NMR (600 MHz, Chloroform-d) δ 8.54 (1H, 
d, J = 8.7 Hz, Ar), 8.17 (1H, d, J = 8.6 Hz, Ar), 7.67–7.75 
(3H, m, Ar), 7.44–7.53 (2H, m, Ar), 6.93 (1H, s, Ar), 6.86 
(1H, d, J = 9.0 Hz, Ar), 6.70 (1H, d, J = 11.5 Hz, Ar), 3.86 
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(2H, q, J = 6.5, 6.0 Hz,  CH2), 3.83 (3H, s,  CH2), 3.68 (3H, 
s,  CH2), 3.52 (1H, s,  CH2), 3.34 (2H, t, J = 6.6 Hz,  CH2), 
3.25 (2H, q, J = 6.8 Hz,  CH2), 2.61 (2H, t, J = 6.3 Hz,  CH2), 
1.88–1.99 (4H, m,  CH2), 1.77 (2H, p, J = 7.3 Hz,  CH2), 
1.43–1.52 (4H, m, 6H), 1.30–1.35 (2H, m,  CH2); MS (ESI) 
m/z (M + 1) 637.3, 308.2, 198.1, 143.0; MS-HR (ESI) Calcd 




The solution of 2-[1-(4-chlorobenzoyl)-5-methoxy-2-meth-
ylindol-3-yl]acetic acid (0.51 g; 1.43 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (CDMT) (0.25 g; 1.42 mmol), 
N- methylmorpholine (0.15 mL; 1.36 mmol) and tetrahy-
drofuran (THF) (10 mL), the solution of N-(1,2,3,4-tetrahy-
dro-9-acrdinyl)-1,7-heptanediamine (0.44 g; 1.41 mmol; 
1f) dissolved in tetrahydrofuran (THF) (3 mL) was added. 
Yield 42.48%, yellow solid; mp 119–121 °C. FTIR (ATR) 
v  (cm−1): 753.9, 1224.5, 1325.4, 1473.8, 1576.8, 2932.1, 
3231.3; 1H NMR (600 MHz, Chloroform-d) δ 8.56 (1H, 
d, J = 8.3 Hz, Ar), 8.16 (1H, d, J = 8.6 Hz, Ar), 7.68–7.74 
(3H, m, Ar), 7.50–7.53 (2H, m, Ar), 7.47 (1H, t, J = 7.8 Hz, 
Ar), 6.92 (1H, s, Ar), 6.85–6.88 (1H, m, Ar), 6.71 (1H, d, 
J = 11.5 Hz, Ar), 3.86–3.90 (2H, m,  CH2), 3.83 (3H, s,  CH2), 
3.67 (3H, s,  CH2), 3.52 (1H, s,  CH2), 3.33–3.38 (2H, m, 
 CH2), 3.23 (2H, q, J = 6.8 Hz,  CH2), 2.61 (2H, t, J = 6.2 Hz, 
 CH2), 1.88–1.99 (4H, m,  CH2), 1.82–1.75 (2H, m,  CH2), 
1.47–1.30 (8H, m,  CH2); MS (ESI) m/z (M + 1) 651.3, 





The solution of 2-[1-(4-chlorobenzoyl)-5-methoxy-2-meth-
ylindol-3-yl]acetic acid (0.48 g; 1.34 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (CDMT) (0.24 g; 1.36 mmol), 
N- methylmorpholine (0.15 mL; 1.36 mmol) and tetrahydro-
furan (THF) (10 mL), the solution of N-(1,2,3,4-tetrahydro-
9-acrdinyl)-1,8-octanediamine (0.44 g; 1.35 mmol; 1g) dis-
solved in tetrahydrofuran (THF) (3 mL) was added. Yield 
48.29%, beige solid; mp 122–124 °C. FTIR (ATR) v  (cm−1): 
754.1, 1224.7, 1325.1, 1473.0, 1568.8, 2927.5, 3227.8; 1H 
NMR (600 MHz, Chloroform-d) δ 8.55 (1H, d, J = 8.5 Hz, 
Ar), 8.16 (1H, d, J = 8.6 Hz, Ar), 7.67–7.75 (3H, m, Ar), 
7.49–7.53 (2H, m, Ar), 7.47 (1H, t, J = 7.7 Hz, Ar), 6.91 (1H, 
s, Ar), 6.87 (1H, d, J = 9.0 Hz, Ar), 6.71 (1H, d, J = 11.5 Hz, 
Ar), 3.87 (2H, t, J = 7.2 Hz,  CH2), 3.84 (3H, s,  CH2), 3.67 
(3H, s,  CH2), 3.52 (1H, s,  CH2), 3.33–3.37 (2H, m,  CH2), 
3.22 (2H, q, J = 6.9 Hz,  CH2), 2.61 (2H, t, J = 6.3 Hz,  CH2), 
1.89–2.00 (4H, m,  CH2), 1.77–1.82 (2H, m,  CH2), 1.39–1.46 
(4H, m,  CH2), 1.29–1.35 (4H, m,  CH2); MS (ESI) m/z 
(M + 1) 665.3, 336.2, 174.1, 143.0; MS-HR (ESI) Calcd for 




The solution of 2-[1-(4-chlorobenzoyl)-5-methoxy-2-meth-
ylindol-3-yl]acetic acid (0.68  g; 1.9  mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (CDMT) (0.34 g; 1.93 mmol), 
N- methylmorpholine (0.21 mL; 1.91 mmol) and tetrahydro-
furan (THF) (10 mL), the solution of N-(1,2,3,4-tetrahydro-
9-acrdinyl)-1,9-nonanediamine (0.65 g; 1.91 mmol; 1h) dis-
solved in tetrahydrofuran (THF) (3 mL) was added. Yield 
17.38%, brown solid; mp 96–98 °C. FTIR (ATR) v  (cm−1): 
754.3, 1219.5, 1355.1, 1471.4, 1587.44, 2926.6, 3238.1; 
1H 1H NMR (600  MHz, Chloroform-d) δ 8.56 (1H, d, 
J = 9.3 Hz, Ar), 8.16 (1H, d, J = 8.6 Hz, Ar), 7.71–7.76 (3H, 
m, Ar), 7.69 (1H, d, J = 8.5 Hz, Ar), 7.45–7.53 (2H, m, Ar), 
6.92 (1H, s, Ar), 6.88 (1H, d, J = 9.0 Hz, Ar), 6.71 (1H, d, 
J = 11.5 Hz, Ar), 3.86–3.91 (2H, m,  CH2), 3.84 (3H, s,  CH2), 
3.67 (3H, s,  CH2), 3.52 (1H, s,  CH2), 3.35 (2H, t, J = 5.8 Hz, 
 CH2), 3.21 (2H, q, J = 6.8 Hz,  CH2), 2.61 (2H, t, J = 6.2 Hz, 
 CH2), 1.89–2.00 (4H, m,  CH2), 1.76–1.84 (2H, m,  CH2), 
1.56–1.64 (4H, m,  CH2), 1.32–1.54 (6H, m,  CH2); MS (ESI) 
m/z (M + 1) 679.3, 350.3, 184.0, 174.1; MS-HR (ESI) Calcd 
for  C41H47ClN4O3: 678.33367. Found: 678.33401.
General procedure for synthesis compounds 3a–3h
For improve solubility, compounds 2a–2h were converted 
into hydrochlorides. Step “b” in Scheme 1 was carried out 
to obtain compounds 3a–3h. The solutions of compound 
2a–2h dissolved in methanol (1 mL) (POCH) was treated 
with excess 1.0 M HCl in diethyl ether (4 mL) (Sigma 
Aldrich). The mixture was stirred for 24 h at room tempera-
ture to crystallize the hydrochloride form which was isolated 




To solution of 2a (0.20 g; 0.34 mmol) in methanol (1 mL) 
1.0 M HCl in diethyl ether (4 mL) was added in excess. 
Yield 80.77%, orange solid, mp 182–184 °C. FTIR (ATR) 
v  (cm−1): 757.0, 1231.4, 1323.7, 1475.2, 1578.5, 2944.1, 
3215.8; 1H NMR (600 MHz, Methanol-d4) δ 8.34 (1H, d, 
J = 8.9 Hz, Ar), 7.84 (1H, t, J = 8.2 Hz, Ar), 7.68–7.73 (3H, 
m, Ar), 7.57–7.61 (2H, m, Ar), 7.52 (1H, t, J = 8.4 Hz, Ar), 
6.96 (1H, d, J = 9.0 Hz, Ar), 6.76 (1H, s, Ar), 6.56 (1H, 
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d, J = 11.5 Hz, Ar), 4.16–4.20 (2H, m,  CH2), 3.78 (2H, q, 
J = 5.9 Hz,  CH2), 3.62 (3H, s,  CH2), 3.41 (2H, s,  CH2), 2.85 
(2H, t, J = 6.2 Hz,  CH2), 2.31–2.36 (2H, m,  CH2), 1.66–1.74 
(4H, m,  CH2); MS (ESI) m/z (M + 1) 581.2, 201.0, 143.0, 





To solution of 2b (0.20 g; 0.34 mmol) in methanol (1 mL) 
1.0 M HCl in diethyl ether (4 mL) was added in excess. 
Yield 86.54%, beige solid, mp 160–162 °C. FTIR (ATR) 
v  (cm−1): 756.1, 1230.2, 1322.7, 1474.5, 1578.1, 2942.2, 
3216.3; 1H NMR (600 MHz, Methanol-d4) δ 8.27 (1H, d, 
J = 8.5 Hz, Ar), 7.83 (1H, d, J = 7.3 Hz, Ar), 7.69–7.74 (3H, 
m, Ar), 7.57–7.60 (2H, m, Ar), 7.49 (1H, t, J = 8.2 Hz, Ar), 
7.00 (1H, s, Ar), 6.86 (1H, d, J = 9.0 Hz, Ar), 6.60 (1H, 
d, J = 9.0 Hz, Ar), 3.87–3.90 (2H, m,  CH2), 3.73 (3H, s, 
 CH2), 3.62 (1H, s,  CH2), 3.43 (2H, q, J = 5.9 Hz,  CH2), 3.01 
(1H, t, J = 5.2 Hz,  CH2), 2.66–2.69 (2H, m,  CH2), 2.03 (2H, 
p, J = 6.6 Hz,  CH2), 1.91–1.97 (4H, m,  CH2); MS (ESI) 
m/z (M + 1) 595.2, 199.1, 143.0; MS-HR (ESI) Calcd for 




To solution of 2c (0.20 g; 0.33 mmol) in methanol (1 mL) 
1.0 M HCl in diethyl ether (4 mL) was added in excess. 
Yield 92.31%, yellow solid, mp 157–159 °C. FTIR (ATR) 
v  (cm−1): 756.3, 1219.7, 1323.4, 1473.8, 1576.9, 2941.4, 
3223.2; 1H NMR (600 MHz, Methanol-d4) δ 8.24 (1H, d, 
J = 8.7 Hz, Ar), 7.83 (1H, t, J = 7.7 Hz, Ar), 7.74 (1H, d, 
J = 9.3 Hz, Ar), 7.67–7.70 (2H, m, Ar), 7.56–7.60 (2H, m, 
Ar), 7.52 (1H, t, J = 8.4 Hz, Ar), 7.00 (1H, s, Ar), 6.84 (1H, 
d, J = 9.0 Hz, Ar), 6.53–6.56 (1H, m, Ar), 3.88–3.92 (2H, 
m,  CH2), 3.71 (3H, s,  CH2), 3.60 (1H, s,  CH2), 3.31 (2H, t, 
J = 6.7 Hz,  CH2), 3.01 (2H, t, J = 5.4 Hz,  CH2), 2.62 (2H, 
t, J = 5.3 Hz,  CH2), 1.91–1.97 (4H, m,  CH2), 1.80 (2H, p, 
J = 8.1, 7.7 Hz,  CH2), 1.63–1.69 (2H, m,  CH2); MS (ESI) 
m/z (M + 1) 609.3, 199.1, 143.0; MS-HR (ESI) Calcd for 




To solution of 2d (0.20 g; 0.32 mmol) in methanol (1 mL) 
1.0 M HCl in diethyl ether (4 mL) was added in excess. 
Yield 87.50%, yellow solid, mp 158–160 °C. FTIR (ATR) 
v  (cm−1): 754.5, 1223.8, 1323.2, 1455.4, 1587.5, 2937.7, 
3207.7; 1H NMR (600 MHz, Methanol-d4) δ 8.33 (1H, d, 
J = 8.5 Hz, Ar), 7.85 (1H, t, J = 8.2 Hz, Ar), 7.75 (1H, d, 
J = 9.3 Hz, Ar), 7.67–7.70 (2H, m, Ar), 7.54–7.59 (3H, m, 
Ar), 7.03 (1H, s, Ar), 6.89 (1H, d, J = 9.0 Hz, Ar), 6.60 (1H, 
d, J = 11.5 Hz, Ar), 3.82–3.86 (2H, m,  CH2), 3.77 (3H, s, 
 CH2), 3.61 (1H, s,  CH2), 3.25–3.28 (2H, m,  CH2), 3.02 (2H, 
t, J = 5.7 Hz,  CH2), 2.65–2.69 (2H, m,  CH2), 2.00–1.93 
(4H, m,  CH2), 1.83 (2H, p, J = 7.6 Hz,  CH2), 1.60 (2H, p, 
J = 7.0 Hz,  CH2), 1.42 (2H, p, J = 9.3, 8.6 Hz,  CH2); MS 
(ESI) m/z (M + 1) 623.3, 199.1, 143.0; MS-HR (ESI) Calcd 




To solution of 2e (0.20 g; 0.31 mmol) in methanol (1 mL) 
1.0 M HCl in diethyl ether (4 mL) was added in excess. Yield 
56.00%, brown solid, mp 83–85 °C. FTIR (ATR) v  (cm−1): 
754.4, 1218.9, 1324.2, 1456.0, 1587.1, 2934.9, 3237.8; 1H 
NMR (600 MHz, Methanol-d4) δ 8.30 (1H, d, J = 8.5 Hz, 
Ar), 7.82–7.87 (1H, m, Ar), 7.75 (1H, d, J = 7.7 Hz, Ar), 
7.64–7.67 (2H, m, Ar), 7.54–7.58 (3H, m, Ar), 7.05 (1H, s, 
Ar), 6.86 (1H, d, J = 9.0 Hz, Ar), 6.59 (1H, d, J = 11.5 Hz, 
Ar), 3.79–3.83 (2H, m,  CH2), 3.78 (3H, s,  CH2), 3.61 (2H, 
s,  CH2), 3.24–3.28 (2H, m,  CH2), 3.02 (2H, t, J = 5.4 Hz, 
 CH2), 2.66 (2H, t, J = 5.1 Hz,  CH2), 1.95–2.00 (4H, m,  CH2), 
1.74 (2H, p, J = 7.4 Hz,  CH2), 1.55 (2H, p, J = 7.0 Hz,  CH2), 
1.40–1.46 (2H, m,  CH2), 1.38–1.31 (2H, m,  CH2); MS (ESI) 
m/z (M + 1) 637.3, 308.2, 174.1, 143.0; MS-HR (ESI) Calcd 




To solution of 2f (0.20 g; 0.31 mmol) in methanol (1 mL) 
1.0 M HCl in diethyl ether (4 mL) was added in excess. 
Yield 72.00%, yellow solid, mp 150–152 °C. FTIR (ATR) 
v  (cm−1): 754.5, 1224.4, 1323.5, 1456.1, 1587.5, 2931.3, 
3207.8; 1H NMR (600 MHz, Methanol-d4) δ 8.36 (1H, d, 
J = 8.6 Hz, Ar), 7.86 (1H, t, J = 7.7 Hz, Ar), 7.76 (1H, d, 
J = 9.3 Hz, Ar), 7.67–7.70 (2H, m, Ar), 7.55–7.60 (3H, m, 
Ar), 7.04 (1H, s, Ar), 6.89–6.92 (1H, m, Ar), 6.63 (1H, d, 
J = 11.5 Hz, Ar), 3.87–3.91 (2H, m,  CH2), 3.80 (3H, s,  CH2), 
3.61 (2H, s,  CH2), 3.21–3.25 (2H, m,  CH2), 3.03 (2H, t, 
J = 5.6 Hz,  CH2), 2.69 (2H, t, J = 5.3 Hz,  CH2), 1.95–2.00 
(4H, m,  CH2), 1.77 (2H, p, J = 7.5 Hz,  CH2), 1.52 (2H, p, 
J = 6.9 Hz,  CH2), 1.27–1.39 (6H, m,  CH2); MS (ESI) m/z 
(M + 1) 651.3, 322.2, 174.1, 139.0; MS-HR (ESI) Calcd for 
 C39H43ClN4O3: 650.30237. Found: 650.30199.





To solution of 2g (0.20 g; 0.30 mmol) in methanol (1 mL) 
1.0 M HCl in diethyl ether (4 mL) was added in excess. 
Yield 83.33%, beige solid, mp 146–148 °C. FTIR (ATR) 
v  (cm−1): 754.3, 1222.6, 1319.9, 1455.9, 1588.0, 2926.5, 
3207.1; 1H NMR (600 MHz, Methanol-d4) δ 8.37 (1H, d, 
J = 8.7 Hz, Ar), 7.86 (1H, t, J = 7.7 Hz, Ar), 7.76 (1H, d, 
J = 8.5 Hz, Ar), 7.66–7.70 (2H, m, Ar), 7.55–7.60 (3H, m, 
Ar), 7.04 (1H, s, Ar), 6.91 (1H, d, J = 9.0 Hz, Ar), 6.64 (1H, 
d, J = 11.5 Hz, Ar), 3.87–3.91 (2H, m,  CH2), 3.80 (3H, s, 
 CH2), 3.61 (2H, s,  CH2), 3.20–3.24 (2H, m,  CH2), 3.02 (2H, 
t, J = 5.8 Hz,  CH2), 2.69 (2H, t, J = 5.4 Hz, 2H), 1.93–2.01 
(4H, m,  CH2), 1.79 (2H, p, J = 7.6 Hz,  CH2), 1.51 (2H, p, 
J = 6.5 Hz,  CH2), 1.25–1.41 (8H, m,  CH2); MS (ESI) m/z 
(M + 1) 665.3, 336.2, 174.1, 143.0; MS-HR (ESI) Calcd for 




To solution of 2h (0.20 g; 0.29 mmol) in methanol (1 mL) 
1.0 M HCl in diethyl ether (4 mL) was added in excess. 
Yield 56.52%, brown solid, mp 146–148 °C. FTIR (ATR) 
v  (cm−1): 753.9, 1218.7, 1397.6, 1468.6, 1601.7, 2916.0, 
3208.0; 1H NMR (600 MHz, Methanol-d4) δ 8.38 (1H, d, 
J = 8.4 Hz, Ar), 7.86 (1H, t, J = 7.7 Hz, Ar), 7.76 (1H, d, 
J = 9.3 Hz, Ar), 7.67–7.71 (2H, m, Ar), 7.55–7.62 (3H, m, 
Ar), 7.04 (1H, s, Ar), 6.94 (1H, d, J = 9.0 Hz, Ar), 6.65 (1H, 
d, J = 11.5 Hz, Ar), 3.90–3.94 (2H, m,  CH2), 3.81 (3H, s, 
 CH2), 3.61 (2H, s,  CH2), 3.20–3.24 (2H, m,  CH2), 3.02 (2H, 
t, J = 5.9 Hz,  CH2), 2.70 (2H, t, J = 5.7 Hz,  CH2), 1.94–2.02 
(4H, m,  CH2), 1.80 (2H, p, J = 7.4 Hz,  CH2), 1.50 (2H, 
p, J = 6.8 Hz,  CH2), 1.27–1.43 (10H, m,  CH2); MS (ESI) 
m/z (M + 1) 679.3, 174.1, 167.0; MS-HR (ESI) Calcd for 
 C41H47ClN4O3: 678.33367. Found: 678.33207.
In vitro inhibition studies on AChE and BuChE
The inhibitory potency of the de novo synthesized com-
pounds against acetycholinoesterase (AChE from electric 
ell, EC 3.1.1.7; Sigma-Aldrich) and butyrylcholinesterase 
(BuChE from equine serum, EC 3.1.1.8; Sigma-Aldrich) was 
measured using Ellman’s method with modifications (Ell-
man GL, et al. 1961; Czarnecka et al. 2018). The inhibitory 
activity of the tested compounds was compared with that 
of the well-known AChE inhibitors tacrine and donepezil. 
The reactive mixture included: dithiobis-(2-nitro)benzoic 
acid solution (0.4 mg/mL), AChE (2 U/mL) or BuChE (4 U/
mL) solution and different tested compound concentrations 
(0.0001–10 µM) (USP XXII-NF XVII United States Phar-
macopeia Convention, Inc. 1990). PBS buffer (pH 8.0) was 
used as a solvent. To start the reaction, acetylthiocholine 
iodide solution (1 mM) was added. Samples were incubated 
at room temperature for 10 min and the change of absorb-
ance was measured at a wavelength of 412 nm (Synergy H1 
spectrophotometer, Bio-Tek). The results were used to cal-
culate  IC50 values for each compound. (i.e. the concentration 
causing 50% inhibition of enzyme activity). All experiments 
were carried out in triplicate for each of the three samples.
Kinetic characterization of AChE and BuChE inhibi‑
tion
Ellman’s method (on 96-well plates) was used to prepare 
a kinetic characterization of AChE and BuChE inhibition 
for the tested compound (3h). A mixture of different con-
centrations of substrate was used: acetylthiocholine iodide 
(AChI) (50–350 µM), four concentrations were used for 
AChE kinetics (4, 7, 14, 21 nM) and three concentrations 
for BuChE kinetics (28, 42, 56 nM), dithiobis-(2-nitro)ben-
zoic acid solution (0.4 mg/mL), AChE solution (2 U/mL) 
or BuChE solution (4 U/mL) (USP XXII-NF XVII United 
States Pharmacopeia Convention, Inc. 1990). The absorb-
ance at 412 nm was measured (Synergy H1 Spectrophotom-
eter, Bio-Tek). The obtained results were used to prepare 
a Lineweaver–Burk plots of 1/velocity versus 1/substrate 
concentration. The Km and Vmax values were calculated and 
the type of enzyme inhibition was determined (Czarnecka 
et al. 2018).
Cytotoxicity studies on HepG2 cell line
Cell line
Cytotoxicity tests were performed using the human hepa-
tocellular liver carcinoma cell line HepG2 (passage 31–38) 
purchased from Health Protection Agency Culture Collec-
tions (ECACC, Salisbury, UK). Eagle’s Minimum Essential 
Medium MEM (Sigma Aldrich, St. Louis, USA) was used 
for the routine culture of cells. Medium was supplemented 
with 10% fetal bovine serum FBS, non-essential amino acid 
solution (Sigma Aldrich, St. Louis, USA) and 1% l-Glu-
tamine solution (Sigma Aldrich, St. Louis, USA). The cells 
were cultured in humidified conditions with 5%  CO2 at 
37 °C, the culture medium was discarded every 2–3 days. 
During passaging, the cells were briefly rinsed with PBS, 
aspirated and then incubated for 5–7 min with 1 mL of 
0.05% trypsin–EDTA solution (Sigma Aldrich, St. Louis, 
USA) at 37 °C. For the cytotoxicity evaluation, one group 
of HepG2 cells was exposed to examined compounds and 
the second one was utilized as a control group.
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Cytotoxicity measurement
Cytotoxicity test was performed using CellTiter 96 Aque-
ous One Solution Reagent containing [3-(4,5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS), stabilized by phenazine ethosulfate 
(PSE). MTS is reduced by living cells, thus forming a 
formazan product, staining the tested probe. The color inten-
sity at 490 nm is directly proportional to the amount of liv-
ing cells in the sample (Technical Bulletin 2019). Cells were 
seeded in a 96-well plate in a density of 10,000 cells per 
well. After 24 h of incubation in appropriate conditions, 
solutions of investigated substances were applied in trip-
licate (volume of injection = 1 µL). These solutions were 
prepared by dissolving substances in DMSO and were sub-
sequently diluted to the required range of injection concen-
trations (100; 50; 25; 10; 5; 2.5; 1.0; 0.5 µM). Additionally, 
cells with 100% viability (injection of 1µL of DMSO into 
each well), 0% viability (10 µL of DMSO) and vehicle con-
trols were tested in triplicate.
The cells were incubated at 37 °C for 24 h in an atmos-
phere containing 5%  CO2 and then 20 µL of the reagent from 
the kit CellTiter 96 Aqueous One Solution Cell Proliferation 
Assay (PROMEGA, Fitchburg, USA) were applied into each 
well. After 80 min of incubation, absorbance was measured 
at 490 nm (TECAN, Infinite M200 Austria).  IC50 was calcu-
lated using nonlinear regression from a semilogarithmic plot 
of incubation concentration versus the percentage of absorb-
ance relative to control cells. Statistical parameters (means 
and standard deviations) were obtained utilizing GraphPad 
Prism software (version 6).
Cytotoxicity studies on EA.hy926 cell line
Cell culture
The EA.hy926 cell line (the human umbilical vein, somatic 
cell hybrid) (American Type Culture Collection) was used 
to evaluate the cytotoxicity after 3 h. The culture medium 
consisted of Dulbecco’s Modified Eagle’s Medium (DMEM) 
(PAN-Biotech) containing 10% Fetal Bovine Serum (Sigma 
Aldrich), 2 mM Glutamine (Sigma Aldrich) and 100 units/
mL penicillin and 100 mg/mL streptomycin (Biological 
Industries). Cells were passaged and kept in an incubator at 
37 °C with 5%  CO2 before the initiation of the assay.
MTT cell viability assay
The MTT test was performed to evaluate cell metabolic 
activity and to determine cell viability. Enzymatically active 
mitochondria reduce the water-soluble MTT (3-(4,5-dimeth-
ylthiazol-2-yl)-2,5 diphenyltetrazoliumbromide) to blue-vio-
let insoluble formazan crystals. At the first day of assay, cells 
were seeded at a density of 104 cells/well in 96-well plates 
and incubated for 24 h at 37 °C and 5%  CO2. After this time, 
culture medium from all wells was removed and replaced by 
100 µL of the compound solution over the range
of concentration (35–1 µM) or by 100 µL of culture 
medium (blank control). Plates were incubated for 24 h at 
37 °C and 5%  CO2. Finally, the culture medium and com-
pound solutions were removed from all wells and replaced 
by 50 µL of the MTT solution (0.75 mg/mL) and incubated 
in the dark for 2 h at 37 °C and 5%  CO2. Then the MTT solu-
tion was carefully removed and 100 µL of DMSO (Serva) 
was added to each well to dissolve the formazan crystals. 
The plates were incubated for 10 min at room temperature.
After incubation, 5 µL of Sorenson’s glycine buffer 
(0.1 M glycine, 0.1 M NaCl, pH 10.5) was added to each 
well. Plates were incubated at room temperature for 5 min. 
Then the absorbance was measured in the microplate reader 
(Synergy H1, BioTek, Winooski, VT, USA) at 570 nm. Cell 
viability was expressed as a percentage of control values 
(blank) (Plumb 1999).
pKa assay
Potassium dihydrogen phosphate, potassium hydroxide, 
methanol (POCH) solution was used to prepare a buffer solu-
tion. Stock phosphorous buffer was prepared from 500 mL 
0.02 M potassium dihydrogen phosphate solution by adding 
500 mL methanol. 35 work buffers were prepared by titrat-
ing stock phosphorus buffer by 0.1 M potassium hydrox-
ide solution in methanol: water (1:1) mix. Work buffer pH 
was set in the range from 5.6 to 12.4 by 0.2 per step. The pH 
measurement was performed at 23 °C using Mettler Toledo 
FiveEasy pH-meter with an LE438 Lab pH electrode (Met-
tler Toledo). HI7004 pH 4.01 buffer solution and HI7007 pH 
7.01 buffer solution (Hanna instruments Inc., Woodsocket 
RI, USA) were used for the calibration of the pH meter. Our 
tested compound solution was 5 µM solution in methanol: 
water (1:1) mix.
Spectrophotometric measurement was performed in a 
96-well plate using Synergy H1 microplate reader (BioTek) 
with Gen5 software (BioTek). The full assay consisted of 35 
UV spectra measurements, one for each working buffer solu-
tion. For the assay, 180 µL sequent working buffer and 20 µL 
tested compound solution was added to each of 35 wells. For 
the blank, 200 µL sequent working buffer only was added 
to every 35 wells. The measurement was performed at 
23 °C, from 280 nm to 380 nm in 1 nm steps. The obtained 
spectra were subtracted from the blank. Results collected 
at 310 nm and 336 nm were selected for further analysis. 
All calculations were performed based on 310/336 nm and 
336/310 nm ratios. The specific pH value for every ionized 
form of the molecule was estimated by finding the small-
est difference between the absorbance ratios of 310/336 nm 
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and 336/310 nm. The pKa value was calculated for both 
ratios. The mean of these two results was considered as the 
final pKa value. The obtained results were compared with 
computer calculations of pKa carried out by online software 
chemicalize.com (ChemAxon 2018) (Musil et al. 2016).
In vitro ABTS and DPPH assay
The antioxidant activity of the synthesized compounds 
(3a–3h) was evaluated based on two different assays: radical 
scavenging activities using 2,2-diphenyl-1-picrylhydrazyl 
(DPPH) assay and ABTS assay. In the ABTS assay, 5 mL of 
a 7 mM aqueous ABTS solution was mixed with 88 μL of 
a 140 mM (2.45 mM final concentration) potassium persul-
fate  (K2S2O8). The mixture was stored at room temperature 
for 16 h. After this time,  ABTS•+ was diluted in methanol; 
absorbance at 734 nm was found to be 0.7 ± 0.02. Solutions 
of each tested compound were dissolved in methanol. The 
decrease in absorbance was recorded at 0 and after 6 min (Re 
et al. 1999; Nenadis et al. 2007).
In the DPPH assay, 50 μL of various concentrations of 
tested compounds were mixed with an equal quantity of 
DPPH solution (0.2 mM). After 30 min of incubation in the 
dark, the absorbance was measured at 517 nm. Compounds 
with antioxidant activity reduce the color
of the DPPH solution (Blois 1958; Chand et al. 2016). 
Both methods were carried out using a Synergy H1 96-well 
microplate (Biotek). All measurements were carried out in 
triplicate with blank solutions each time and compared to 
the references. Compounds concentration providing 50% 
inhibition  (FRS50) was calculated from the graph plotted 
as inhibition percentage against compound concentration.
Molecular modeling
Docking studies were performed with GoldSuite 5.1 (CCDC) 
(Lu et al. 2014). Three-dimentional structure of all tested 
ligands was prepared with Corina on-line (Molecular Net-
works and Altamira) (Mailloux et al. 2001; Corina on-line 
2019). Sybyl X-1.1 (Tripos) was used to check atom types, 
add hydrogen atoms and assign Gasteiger-Marsili charges 
(Gasteiger and Marsili 1978; Sybyl-X 1.1 2010). Due to the 
high conformational freedom of the amino acids needed for 
the ligand binding in the active site of acetylcholinester-
ase (Phe330 and Trp279), prepared ligands were docked to 
three structures of acetylcholinesterase (PDB codes:1EVE, 
1ACJ and 2CKM). The acetylcholinesterase complex with 
bis-(7)-tacrine (PDB code: 2CKM) was chosen as the most 
suitable for docking as it gave the most consistent results 
in preliminary studies. The butyrylcholinesterase complex 
with butyrate (PDB code: 1P0I) was chosen for docking 
studies on this enzyme. Protein structures were prepared 
with Hermes 1.7.0. to protonate all histidine residues in 
Nε position, add all hydrogen atoms, remove unnecessary 
ligands and water molecules. Docking was performed into 
binding sites composed of all amino acids within radius of 
10 Å from bis-(7)-tacrine for AChE and 20 Å from the glyc-
erol molecule present in the active center of BuChE. Stand-
ard settings of the genetic algorithm were applied. Ten poses 
per ligand, sorted by GoldScore (for AChE) and ChemScore 
(for BChE) function values were obtained. PyMOL 0.99rc6 
(DeLano Scientific LLC) was used to visualize the results of 
docking (Bajda et al. 2015; PyMOL 0.99rc6 2006).
Results and discussion
Synthesis
The new acetylcholinesterase inhibitors were created by 
connecting diamine derivatives of tetrahydroacridine with 
indomethacin. Compounds 1a–1h (synthesis described by 
Szymanski et al. 2011) were connected to an acid mole-
cule by aliphatic linker (Scheme 1). Reactions were carried 
out in the presence of 2-chloro-4,6-dimethyl-1,3,5-triazine 
(CDMT) and N-methylmorpholine. CDMT was necessary 
for the activation of the carboxylic group in indomethacin. 
CDMT, indomethacin and N-methylmorpholine were dis-
solved in tetrahydrofuran (THF). Next, amines 1a–1h were 
added. After 24 h at − 5 °C products 2a–2h were obtained. 
The reactions were monitored by TLC. Compounds 2a–2h 
were purified by flash chromatography using a PuriFlash 430 
(Interchem Inc). In the last stage, 2a–2h were converted to 
3a–3h hydrochlorides. They were dissolved in methanol and 
HCl in ether was added (room temp., 24 h). Hydrochlorides 
3a–3h were crystallized.
In vitro inhibition studies on AChE and BuChE
The inhibitory activity against AChE and BuChE for de novo 
synthesized compounds
3a–3h was measured using Ellman’s method (Ellman et al. 
1961; Czarnecka et al. 2018). The activities of the tested 
compounds were compared with tacrine and donepezil 
(well-known cholinesterase inhibitors).  IC50 values for 
tested compound are shown in Table 1. Compounds 3b–3h 
exhibit high inhibitory activity against AChE. The  IC50 val-
ues for 3b–3h ranging from 10 to 260 nM. Compound 3a has 
lower inhibitory potency than others, with an  IC50 value of 
7078 nM. In comparison to tacrine  (IC50 = 174 nM), 3b–3d 
and 3f–3h revealed higher inhibitory activity. Compared to 
donepezil  (IC50 = 87 nM), 3b–3d and 3g–3h revealed higher 
inhibition. The most active compound against AChE was 3h 
 (IC50 = 10 nM), with the longest alkyl linker (nine carbon 
atoms).
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Compounds 3d  (IC50 = 30 nM) and 3f  (IC50 = 6 nM) were 
more active against BuChE than tacrine  (IC50 = 32 nM). All 
of the compounds with  IC50 from 6 to 335 nM revealed a 
higher inhibitory potency against BuChE than donepezil 
 (IC50 = 9757 nM).
Compound 3h was more active against AChE than 
tacrine (18 times more) and donepezil (9 times more) and 
was selected for kinetic studies of the AChE inhibition. 
Compound 3f was more active against BuChE than tacrine 
(5 times more) and donepezil (1501 times more) and was 
selected for kinetic studies of BuChE inhibition.
Kinetic characterization of AChE and BChE inhibition
The study of the inhibitory mechanism against AChE 
showed 3h to have the highest activity  (IC50 = 10 nM). The 
activity of enzymes at various substrate concentrations was 
measured. The Lineweaver–Burk plot of reciprocal veloc-
ity versus reciprocal substrate concentrations for the vari-
ous inhibitor concentrations was created. The Km values 
decreased, and Vmax values increase at increasing inhibitor 
concentrations.
Compound 3h demonstrated mixed-type inhibition 
against AChE and BuChE (Figs. 1 and 2) (Czarnecka et al. 
2018).
Cytotoxicity studies on HepG2 cell line
To compare the cytotoxicity of investigated sub-
stances,  IC50 was calculated: the inhibitory concentra-
tion which reduces the viability of the cells’ population 
to 50% from the control viability (100%). Derivatives of 
2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-
N-(ω-(5,6,7,8tetrahydroacridin-9-ylamino)ethyl) acetamide 
hydro-chlorides values of  IC50 were relatively uniform and 
vary from 5 µM (compound 3d) to 17 µM (compound 3c).
Cytotoxicity studies on EA.hy926 cell line
The EA.hy926 cells are immortalized human vein endothe-
lial cells (HUVEC), which show morphological, pheno-
typic and functional characteristics of human endothelial 
cells, without the limited lifespan. They are considered a 
suitable model for drug screening (Lu et al. 2014). The 
endothelium is a barrier between blood and tissues, con-
trolling coagulation and the adhesion of immunocompetent 
Table 1  The activity of tested 
compounds against AChE and 
BuChE
A Compound concentration (mean ± SD of the three independent experiments) for 50% inactivation of 
AChE










3a 7086 ± 1355 289 ± 36 0.04 24.56
3b 42 ± 4 335 ± 33 8.05 0.12
3c 25 ± 2 229 ± 30 9.16 0.11
3d 62 ± 8 30 ± 4 0.49 2.06
3e 261 ± 6 246 ± 26 0.94 1.06
3f 99 ± 3 7 ± 1 0.07 15.25
3g 29 ± 2 241 ± 44 8.40 0.12
3h 10 ± 1 57 ± 4 6.02 0.17
Tacrine 174 ± 31 32 ± 5 0.19 5.40
Donepezil 87 ± 15 9757 ± 1113 112.17 0.01
Fig. 1  Lineweaver-Burk plot showing a mixed-type AChE inhibition 
for 3h 
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cells, and modulating the vascular tone. Many chemical 
agents or chronic inflammatory diseases injure the vascular 
endothelium.
Due to injury, the endothelium might lose its integrity 
leading to cell necrosis or apoptosis (Mailloux et al. 2001). 
The cytotoxicity of 3h was investigated on EA.hy926 cell 
line. The  IC50 value was of 20 ± 2 µM. It might be concluded 
that 3h was slightly less toxic against EA.hy926 cells than on 
HepG2 cells and did not cause strong injury of endothelial 
cells (Fig. 3).
pKa assay
pKa is an important physical property, especially for the 
drug industry. This study used the methodology developed 
by Musil et al. (2016). Our spectrophotometric screening 
method allowed us to determine two pKa values of com-
pound 3h within the pH range from 5.6 to 12.4. The change 
of UV spectra is presented in Fig. 4. Both pKa values were 
estimated experimentally and by modelling to estimate the 
specific pH value for each ionized form (Fig. 5). pKa was 
calculated by regression. The experimental  pKa1 value is 
close to the strongest basic pKa value calculated by Che-
mAxon software; however, a large difference was observed 
for  pKa2 (Table 2).
In vitro ABTS and DPPH assay
To prove the antioxidant activities of new hybrids (3a–3h), 
DPPH and ABTS assays were used (Table 3). Trolox was 
selected as a positive control. Tacrine and indomethacin 
served as negative standards as they show negligible rad-
ical-capturing abilities. Surprisingly, the combination of 

























concentration of the compound solution (μM)
Fig. 3  Percentage of EA.hy926 cell viability relative to different con-
centrations of 3h 
Fig. 4  UV spectra of compound 
3h at different pH
261Chemical Papers (2021) 75:249–264 
1 3
tacrine and indomethacin with an aliphatic chain improved 
antioxidant activity. Generally, compounds with longer 
linkers show better activity. Both studies confirmed that 
the most active compound was 3h with nine carbon atoms 
in the chain, as confirmed by Ellman.
Molecular modeling
Molecular modeling studies were performed to explain 
how the tested compounds interacted with cholinesterases. 
All derivatives demonstrated one predominant binding 
mode with AChE, similar to the one of bis-(7)-tacrine in 
the crystal structure (PDB code: 2CKM). The most active 
derivative (3h) is shown in Fig. 6. The tacrine fragment 
was located in the catalytic active site, creating charac-
teristic π − π stacking and cation− π interactions with 
Trp84 and Phe330 and forming a hydrogen bond between 
the protonated nitrogen atom and oxygen atom from car-
bonyl group of His440. The linker was directed toward 
the active site entrance where a fragment of indometha-
cin was involved in aromatic interactions, especially with 
Trp279 from peripheral anionic site (PAS). The length 
of the linker had a direct impact on how indomethacin 
interacted with the PAS. This fragment in ligands with a 
shorter linker (3b–3d) created π–π stacking with Tyr70 
and Trp279, similarly to the second tacrine moiety of bis-
(7)-tacrine. Optimal interaction was ensured if four car-
bon atoms were present in the linker (3c). Longer alkyl 
chains (compounds 3e–3h) led to the lack of interaction 
of indomethacin with the Tyr70. However, two longest 
linkers (derivatives 3g and 3h) allowed for the formation 
Fig. 5  Scatter plots of obtained 
for compound 3h with regres-
sion equation
Table 2  Experimental and computer calculated pKa values of compound 3h 
pKa1 310/336 nm pKa1 336/310 nm pKa1 pKa2 310/336 nm pKa2 336/310 nm pKa2 pKa strong basic Che-
mAxon
pKa strong acidic 
ChemAxon
8.94 8.70 8.82 11.67 11.50 11.58 8.89 15.59
Table 3  In vitro DPPH and ABTS assay results
a Each value is the mean of triplicate determinations ± SD
Compound ABTS (FRS50, mM)a DPPH (FRS50, mM)a
3a 3.96 ± 0.17 > 10
3b 2.36 ± 0.49 > 10
3c 3.85 ± 0.61 > 10
3d 1.34 ± 0.13 > 10
3e > 10 > 10
3f 0.89 ± 0.11 5.03 ± 0.67
3g 1.41 ± 0.14 3.62 ± 0.46
3h 0.51 ± 0.04 0.60 ± 0.12
Tacrine > 10 > 10
Indomethacine > 10 > 10
Trolox 4.2 × 10−2 ± 0.4 × 10−2 4.86 ×  10−3 ± 0.42 × 10−3
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of specific interaction with Ser286 which increased the 
strength of binding of these ligands with the AChE.
In spite of the fact that the active site of butyrylcho-
linesterase is wider than the active site of acetylcholinester-
ase, final conformations of ligands were similar. The most 
active compound 3f was used to illustrate the binding mode 
(Fig. 7). The tacrine moiety presented the same conforma-
tion as before. It created π–π stacking and cation–π interac-
tions with Trp82 and H-bond between protonated nitrogen 
and carbonyl group of His438. The indomethacin moiety 
enforced extended conformation for all derivatives despite 
differences in the length of the linker. Ligands with a shorter 
linker interacted with reduced PAS of butyrylcholinesterase, 
while derivatives with a longer chain reached farther and 
bound to Phe278. The optimal length of the linker (seven 
carbon atoms for compound 3f) allowed for optimal aromatic 
interactions between indomethacin and Phe278. Changing 
the length of the linker resulted in the weakening or loss 
of these interactions, and a consequent decrease in activity.
Conclusions
The development of drugs that could modulate multiple tar-
gets simultaneously in the multifactorial processes involved 
in Alzheimer’s disease is a very good direction for obtaining 
effective drugs. In these studies, we present the synthesis 
and evaluation of de novo synthesized hybrids formed from 
the connection of 9-amino-1,2,3,4-tetrahydroacridine and 
indomethacin. As a link, different alkyl chains were used.
Fig. 6  Binding mode of com-
pound 3h (orange sticks) in 
the active site of AChE. Parts 
of the active site elements are 
color-coded: yellow, catalytic 
triad; magenta, anionic site; 
orange, acyl pocket; cyan, oxy-
anion hole; green, PAS. The box 
depicts a detailed view of bind-
ing site with compound 3h 
Fig. 7  Binding mode of 
compound 3f (orange sticks) 
in the active site of BuChE. 
Parts of active site are color-
coded: yellow, catalytic 
triad; magenta, anionic site; 
orange, acyl pocket; cyan, oxy-
anion hole; green, PAS. The box 
depicts a detailed view of the 
binding site with compound 3f 
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The inhibitory potencies against AChE and BuChE of 
received compounds were determined. Results were com-
pared with the activity of well-known cholinesterase inhibi-
tors (tacrine, donepezil). The results show high inhibitory 
potency of tested compounds, with  IC50 in low micromolar 
and submicromolar range (7.086 µM and 0.009 µM). Most of 
them have a higher potency than the reference compounds. 
For the most active compounds kinetic studies
were performed. Mix-type AChE and BChE inhibition 
by 3h was determined by spectrophotometry. In addition, 
the new compounds exerted low toxicity on the tested cells 
(HepG2 and EA.hy926), indicating that 3h could be safer 
than tacrine but with good bioavailability. Moreover, the 
compounds showed antioxidant effects in DDPH and ABTS 
studies. New compounds have many features that can be 
useful in the fight against Alzheimer’s disease: they act 
simultaneously on several targets, they show lower toxicity 
than the reference compound—tacrine. The most promising 
compound (3h) can be used to further research its useful-
ness as a potential drug. Our results and those of Zhi-Qiang 
Cheng et al., indicate that indole derivatives can be promis-
ing in the formation of hybrids with tacrine in the search 
for new drugs for Alzheimer’s disease. Such hybrids show a 
significant reduction in hepatotoxicity compared to tacrine 
and stronger inhibition of cholinesterases.
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